{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:51:48Z","timestamp":1789195908970,"version":"build-2803163510"},"reference-count":143,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Millions of people worldwide have chronic kidney disease (CKD). Affected patients are at high risk for cardiovascular (CV) disease for several reasons. Among various comorbidities, CKD is associated with the more severe forms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This is particularly true for patients receiving dialysis or for kidney recipients. From the start of the SARS-CoV-2 pandemic, several CV complications have been observed in affected subjects, spanning acute inflammatory manifestations, CV events, thrombotic episodes and arrythmias. Several pathogenetic mechanisms have been hypothesized, including direct cytopathic viral effects on the myocardium, endothelial damage and hypercoagulability. This spectrum of disease can occur during the acute phase of the infection, but also months after recovery. This review is focussed on the CV complications of coronavirus disease 2019 (COVID-19) with particular interest in their implications for the CKD population.<\/jats:p>","DOI":"10.1093\/ndt\/gfad170","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T05:07:31Z","timestamp":1695964051000},"page":"177-189","source":"Crossref","is-referenced-by-count":20,"title":["COVID-19 and cardiovascular disease in patients with chronic kidney disease"],"prefix":"10.1093","volume":"39","author":[{"given":"Lucia","family":"Del Vecchio","sequence":"first","affiliation":[{"name":"Department of Nephrology and Dialysis, Sant'Anna Hospital, ASST Lariana , Como , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1467-1492","authenticated-orcid":false,"given":"Olga","family":"Balafa","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospital of Ioannina , Ioannina , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Dounousi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, School of Health Sciences, University of Ioannina , Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ekart","sequence":"additional","affiliation":[{"name":"Department of Dialysis, Clinic for Internal Medicine, University Medical Center Maribor , Maribor , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Fernandez","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3387-2123","authenticated-orcid":false,"given":"Patrick B","family":"Mark","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-4018","authenticated-orcid":false,"given":"Pantelis","family":"Sarafidis","sequence":"additional","affiliation":[{"name":"1st Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki , Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M","family":"Valdivielso","sequence":"additional","affiliation":[{"name":"Vascular and Renal Translational Research Group, Institute for Biomedical Research on Lleida (IRBLleida) , Lleida , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0577-7081","authenticated-orcid":false,"given":"Charles J","family":"Ferro","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, University Hospitals Birmingham and Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mallamaci","sequence":"additional","affiliation":[{"name":"Francesca Mallamaci Department of Nephrology, Dialysis, and Transplantation Azienda Ospedaliera \u201cBianchi-Melacrino-Morelli\u201d & CNR-IFC , Reggio Calabria , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"2024013104473825700_bib1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"2024013104473825700_bib2","doi-asserted-by":"crossref","first-page":"m4677","DOI":"10.1136\/bmj.m4677","article-title":"Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study","volume":"371","author":"Xie","year":"2020","journal-title":"BMJ"},{"key":"2024013104473825700_bib3","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/ndt\/gfaa179","article-title":"ERACODA: the European database collecting clinical information of patients on kidney replacement therapy with COVID-19","volume":"35","author":"Noordzij","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2024013104473825700_bib4","author":"John's Hopkins University and Medicine"},{"key":"2024013104473825700_bib5","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41597-022-01534-9","article-title":"ISARIC-COVID-19 dataset: a prospective, standardized, global dataset of patients hospitalized with COVID-19","volume":"9","author":"ISARIC Clinical Characterization Group","year":"2022","journal-title":"Sci Data"},{"key":"2024013104473825700_bib6","doi-asserted-by":"crossref","first-page":"e0001187","DOI":"10.1371\/journal.pgph.0001187","article-title":"Risk factors for SARS-CoV-2 related mortality and hospitalization before vaccination: a meta-analysis","volume":"2","author":"Marmor","year":"2022","journal-title":"PLOS Glob Public Health"},{"key":"2024013104473825700_bib7","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/ndt\/gfab200","article-title":"ERACODA Collaborators. COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study","volume":"36","author":"Goffin","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2024013104473825700_bib8","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/ndt\/gfac246","article-title":"ERACODA Collaborators. The Clinical Frailty Scale as a triage tool for ICU admission of dialysis patients with COVID-19: an ERACODA analysis","volume":"37","author":"Bouwmans","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2024013104473825700_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2215\/CJN.0000000000000087","article-title":"Clinical outcomes and vaccine effectiveness for SARS-CoV-2 infection in people attending advanced CKD clinics: a retrospective provincial cohort study","volume":"18","author":"Roushani","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024013104473825700_bib10","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(22)01656-7","article-title":"Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales","volume":"400","author":"Agrawal","year":"2022","journal-title":"Lancet North Am Ed"},{"key":"2024013104473825700_bib11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s44161-022-00029-5","article-title":"The pathological maelstrom of COVID-19 and cardiovascular disease","volume":"1","author":"Giacca","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"2024013104473825700_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-022-00907-1","article-title":"The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implications","volume":"7","author":"Ning","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2024013104473825700_bib13","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1093\/cvr\/cvaa267","article-title":"SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes","volume":"116","author":"Bojkova","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2024013104473825700_bib14","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.stemcr.2021.02.008","article-title":"SARS-CoV-2 infects human pluripotent stem cell-derived cardiomyocytes, impairing electrical and mechanical function","volume":"16","author":"Marchiano","year":"2021","journal-title":"Stem Cell Rep"},{"key":"2024013104473825700_bib15","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41374-022-00783-x","article-title":"Characterization of COVID-19-associated cardiac injury: evidence for a multifactorial disease in an autopsy cohort","volume":"102","author":"Hanson","year":"2022","journal-title":"Lab Invest"},{"key":"2024013104473825700_bib16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jacc.2020.11.031","article-title":"Pathological evidence for SARS-CoV-2 as a cause of myocarditis: JACC review topic of the week","volume":"77","author":"Kawakami","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024013104473825700_bib17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/CIRCULATIONAHA.120.050754","article-title":"COVID-19-associated nonocclusive fibrin microthrombi in the heart","volume":"143","author":"Bois","year":"2021","journal-title":"Circulation"},{"key":"2024013104473825700_bib18","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1161\/CIRCULATIONAHA.120.051828","article-title":"Microthrombi as a major cause of cardiac injury in COVID-19: a pathologic study","volume":"143","author":"Pellegrini","year":"2021","journal-title":"Circulation"},{"key":"2024013104473825700_bib19","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1161\/CIRCRESAHA.121.318902","article-title":"SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2","volume":"128","author":"Lei","year":"2021","journal-title":"Circ Res"},{"key":"2024013104473825700_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41586-021-03491-6","article-title":"Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia","volume":"594","author":"Braga","year":"2021","journal-title":"Nature"},{"key":"2024013104473825700_bib21","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/S2666-5247(20)30223-8","article-title":"COVID-19 cytokine storm syndrome: a threshold concept","volume":"2","author":"Chen","year":"2021","journal-title":"Lancet Microbe"},{"key":"2024013104473825700_bib22","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3390\/cells10040916","article-title":"Inflammasome activation-induced hypercoagulopathy: impact on cardiovascular dysfunction triggered in COVID-19 patients","volume":"10","author":"Gedefaw","year":"2021","journal-title":"Cells"},{"key":"2024013104473825700_bib23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s11906-008-0076-0","article-title":"Pharmacologic modulation of ACE2 expression","volume":"10","author":"Soler","year":"2008","journal-title":"Curr Hypertens Res"},{"key":"2024013104473825700_bib24","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/ckj\/sfac001","article-title":"Should we continue to use renin-angiotensin-aldosterone system blockers in patients with COVID-19?","volume":"15","author":"Copur","year":"2022","journal-title":"Clin Kidney J"},{"key":"2024013104473825700_bib25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/M20-1515","article-title":"Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review","volume":"173","author":"Mackey","year":"2020","journal-title":"Ann Intern Med"},{"key":"2024013104473825700_bib26","doi-asserted-by":"crossref","first-page":"e213594","DOI":"10.1001\/jamanetworkopen.2021.3594","article-title":"Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis","volume":"4","author":"Baral","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2024013104473825700_bib27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11684-021-0850-9","article-title":"Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with\/without hypertension","volume":"16","author":"Wang","year":"2022","journal-title":"Front Med"},{"key":"2024013104473825700_bib28","doi-asserted-by":"crossref","first-page":"916509","DOI":"10.3389\/fcvm.2022.916509","article-title":"Renin-angiotensin-system inhibitors are associated with lower in-hospital mortality in COVID-19 patients aged 80 and older","volume":"9","author":"Spannella","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2024013104473825700_bib29","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ Res"},{"key":"2024013104473825700_bib30","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1097\/CCM.0000000000005589","article-title":"for ARBs CORONA I Investigators. Renin-angiotensin system pathway therapeutics associated with improved outcomes in males hospitalized with COVID-19","volume":"50","author":"Rocheleau","year":"2022","journal-title":"Crit Care Med"},{"key":"2024013104473825700_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-2600(20)30558-0","article-title":"Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial","volume":"9","author":"Cohen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024013104473825700_bib32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jama.2020.25864","article-title":"BRACE CORONA Investigators. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial","volume":"325","author":"Lopes","year":"2021","journal-title":"JAMA"},{"key":"2024013104473825700_bib33","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(21)00214-9","article-title":"ACEI-COVID Investigators. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial","volume":"9","author":"Bauer","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024013104473825700_bib34","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.eclinm.2021.100962","article-title":"Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial","volume":"37","author":"Duarte","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2024013104473825700_bib35","doi-asserted-by":"crossref","first-page":"100957","DOI":"10.1016\/j.eclinm.2021.100957","article-title":"A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19","volume":"37","author":"Puskarich","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2024013104473825700_bib36","first-page":"573","article-title":"Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial","volume":"22","author":"Hockham","year":"2021","journal-title":"CLARITY Investigators."},{"key":"2024013104473825700_bib37","doi-asserted-by":"crossref","first-page":"e062895","DOI":"10.1136\/bmjopen-2022-062895","article-title":"Protocol for a 30-day randomised, parallel-group, non-inferiority, controlled trial investigating the effects of discontinuing renin-angiotensin system inhibitors in patients with and without COVID-19: the RASCOVID-19 trial","volume":"12","author":"Kliim-Hansen","year":"2022","journal-title":"BMJ Open"},{"key":"2024013104473825700_bib38","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2215\/CJN.18961220","article-title":"ERACODA Collaborators. Renin-angiotensin system blockers and the risk of covid-19-related mortality in patients with kidney failure","volume":"16","author":"Soler","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024013104473825700_bib39","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCRESAHA.121.317997","article-title":"COVID-19 and cardiovascular disease","volume":"128","author":"Chung","year":"2021","journal-title":"Circ Res"},{"key":"2024013104473825700_bib40","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.dsx.2020.03.013","article-title":"Cardiovascular disease and COVID-19","volume":"14","author":"Bansal","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"2024013104473825700_bib41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11883-021-00935-2","article-title":"COVID and cardiovascular disease: what we know in 2021","volume":"23","author":"Chilazi","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"2024013104473825700_bib42","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/eurheartj\/ehab696","article-title":"European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1\u2014epidemiology, pathophysiology, and diagnosis","volume":"43","year":"2022","journal-title":"Eur Heart J"},{"key":"2024013104473825700_bib43","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ajem.2022.01.028","article-title":"Clinical update on COVID-19 for the emergency clinician: presentation and evaluation","volume":"54","author":"Long","year":"2022","journal-title":"Am J Emerg Med"},{"key":"2024013104473825700_bib44","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jamacardio.2020.3557","article-title":"Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)","volume":"5","author":"Puntmann","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2024013104473825700_bib45","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.jcmg.2020.05.004","article-title":"Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging","volume":"13","author":"Huang","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2024013104473825700_bib46","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/s41591-022-01837-9","article-title":"CISCO-19 Consortium. A multisystem, cardio-renal investigation of post-COVID-19 illness","volume":"28","author":"Morrow","year":"2022","journal-title":"Nat Med"},{"key":"2024013104473825700_bib47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/CRD.0000000000000422","article-title":"Comprehensive review of cardiovascular complications of coronavirus disease 2019 and beneficial treatments","volume":"30","author":"Welty","year":"2022","journal-title":"Cardiol Rev"},{"key":"2024013104473825700_bib48","doi-asserted-by":"crossref","first-page":"104185","DOI":"10.1016\/j.archger.2020.104185","article-title":"Clinical characteristics of 312 hospitalized older patients with COVID-19 in Wuhan, China","volume":"91","author":"Li","year":"2020","journal-title":"Arch Gerontol Geriatr"},{"key":"2024013104473825700_bib49","doi-asserted-by":"crossref","first-page":"1039655","DOI":"10.3389\/fcvm.2022.1039655","article-title":"Myocardial injury and its correlation to mortality in hospitalized COVID-19 patients: a retrospective cohort study","volume":"9","author":"Ababneh","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2024013104473825700_bib50","doi-asserted-by":"crossref","first-page":"2103168","DOI":"10.1183\/13993003.03168-2021","article-title":"Cardiovascular outcomes in patients with chronic kidney disease and COVID-19: a multi-regional data-linkage study","volume":"60","author":"Lambourg","year":"2022","journal-title":"Eur Respir J"},{"key":"2024013104473825700_bib51","doi-asserted-by":"crossref","first-page":"e020910","DOI":"10.1161\/JAHA.121.020910","article-title":"Association of kidney disease with outcomes in covid-19: results from the American Heart Association COVID-19 Cardiovascular Disease Registry","volume":"10","author":"Rao","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2024013104473825700_bib52","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1159\/000514467","article-title":"COVID-19 in chronic kidney disease: the impact of old and novel cardiovascular risk factors","volume":"50","author":"Podest\u00e0","year":"2021","journal-title":"Blood Purif"},{"key":"2024013104473825700_bib53","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3346\/jkms.2020.35.e434","article-title":"Association between chronic kidney disease or acute kidney injury and clinical outcomes in COVID-19 patients","volume":"35","author":"Kang","year":"2020","journal-title":"J Korean Med Sci"},{"key":"2024013104473825700_bib54","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1007\/s00392-020-01766-y","article-title":"Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study","volume":"110","author":"Ameri","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2024013104473825700_bib55","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.ajkd.2020.09.003","article-title":"STOP-COVID Investigators. Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States","volume":"77","author":"Flythe","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2024013104473825700_bib56","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/j.ajkd.2021.01.003","article-title":"COVID-19 among US dialysis patients: risk factors and outcomes from a National Dialysis Provider","volume":"77","author":"Hsu","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2024013104473825700_bib57","doi-asserted-by":"crossref","first-page":"755","DOI":"10.34067\/KID.0003672020","article-title":"Chronic hemodialysis patients hospitalized with COVID-19: short-term outcomes in the Bronx, New York","volume":"1","author":"Fisher","year":"2020","journal-title":"Kidney360"},{"key":"2024013104473825700_bib58","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1080\/0886022X.2020.1816179","article-title":"Clinical characteristics and outcome of hemodialysis patients with COVID-19: a large cohort study in a single Chinese center","volume":"42","author":"Zou","year":"2020","journal-title":"Ren Fail"},{"key":"2024013104473825700_bib59","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2215\/CJN.04160320","article-title":"Clinical features of maintenance hemodialysis patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"15","author":"Wu","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024013104473825700_bib60","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2022.02.016","article-title":"COVID-19 and thrombosis: the role of hemodynamics","volume":"212","author":"Sastry","year":"2022","journal-title":"Thromb Res"},{"key":"2024013104473825700_bib61","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID-19 and its implications for thrombosis and anticoagulation","volume":"135","author":"Connors","year":"2020","journal-title":"Blood"},{"key":"2024013104473825700_bib62","doi-asserted-by":"crossref","first-page":"10372","DOI":"10.3390\/ijms231810372","article-title":"Venous thromboembolic disease in COVID-19. Pathophysiology, therapy and prophylaxis","volume":"23","author":"Dybovska","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024013104473825700_bib63","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1111\/jth.14872","article-title":"Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19","volume":"18","author":"Whyte","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2024013104473825700_bib64","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1113\/EP089404","article-title":"COVID-19 coagulopathy - what should we treat?","volume":"107","author":"Chowdary","year":"2022","journal-title":"Exp Physiol"},{"key":"2024013104473825700_bib65","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1161\/CIRCULATIONAHA.120.050354","article-title":"Severe COVID-19 is a microvascular disease","volume":"142","author":"Lowenstein","year":"2020","journal-title":"Circulation"},{"key":"2024013104473825700_bib66","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood-2018-11-882993","article-title":"Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms","volume":"133","author":"Jackson","year":"2019","journal-title":"Blood"},{"key":"2024013104473825700_bib67","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1161\/CIRCULATIONAHA.120.049015","article-title":"Heparin-induced thrombocytopenia in severe COVID-19","volume":"142","author":"Daviet","year":"2020","journal-title":"Circulation"},{"key":"2024013104473825700_bib68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.thromres.2021.04.016","article-title":"Increased prevalence of heparin induced thrombocytopenia in COVID-19 patients","volume":"203","author":"Preti","year":"2021","journal-title":"Thromb Res"},{"key":"2024013104473825700_bib69","first-page":"790","article-title":"et al. Therapeutic anticoagulation","volume":"385","author":"ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators","year":"2021","journal-title":"N Engl J Med"},{"key":"2024013104473825700_bib70","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc2013656","article-title":"Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19","volume":"383","author":"Bowles","year":"2020","journal-title":"N Engl J Med"},{"key":"2024013104473825700_bib71","doi-asserted-by":"crossref","first-page":"101402","DOI":"10.1016\/j.beha.2022.101402","article-title":"COVID-19 and antiphospholipid antibodies","volume":"35","author":"Butt","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"key":"2024013104473825700_bib72","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.chest.2020.11.005","article-title":"Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis","volume":"159","author":"Jim\u00e9nez","year":"2021","journal-title":"Chest"},{"key":"2024013104473825700_bib73","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/rth2.12439","article-title":"Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis","volume":"4","author":"Nopp","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"2024013104473825700_bib74","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s11239-021-02394-7","article-title":"Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review","volume":"51","author":"Jenner","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"2024013104473825700_bib75","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40560-021-00535-x","article-title":"The incidence of pulmonary thromboembolism in COVID-19 patients admitted to the intensive care unit: a meta-analysis and meta-regression of observational studies","volume":"9","author":"Ng","year":"2021","journal-title":"J Intensive Care"},{"key":"2024013104473825700_bib76","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1001\/jama.2020.13372","article-title":"Thrombosis in hospitalized patients with COVID-19 in a New York City health system","volume":"324","author":"Bilaloglu","year":"2020","journal-title":"JAMA"},{"key":"2024013104473825700_bib77","doi-asserted-by":"crossref","first-page":"e14910","DOI":"10.1111\/ijcp.14910","article-title":"Venous thromboembolism is linked to severity of disease in COVID-19 patients: a systematic literature review and exploratory meta-analysis","volume":"75","author":"Srivastava","year":"2021","journal-title":"Int J Clin Prac"},{"key":"2024013104473825700_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2021.06.014","article-title":"Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes","volume":"205","author":"Rivera-Caravaca","year":"2021","journal-title":"Thromb Res"},{"key":"2024013104473825700_bib79","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.2021.17272","article-title":"ACTIV-4B Investigators. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial","volume":"326","author":"Connors","year":"2021","journal-title":"JAMA"},{"key":"2024013104473825700_bib80","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/joim.13205","article-title":"Direct oral anticoagulant use and risk of severe COVID-19","volume":"289","author":"Flam","year":"2021","journal-title":"J Intern Med"},{"key":"2024013104473825700_bib81","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1055\/a-1414-5216","article-title":"Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial","volume":"121","author":"Gonzalez-Ochoa","year":"2021","journal-title":"Thromb Haemost"},{"key":"2024013104473825700_bib82","doi-asserted-by":"crossref","first-page":"n2400","DOI":"10.1136\/bmj.n2400","article-title":"RAPID Trial Investigators. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial","volume":"375","author":"Sholzberg","year":"2021","journal-title":"BMJ"},{"key":"2024013104473825700_bib83","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","article-title":"HEP-COVID Investigators. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID Randomized Clinical Trial","volume":"181","author":"Spyropoulos","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2024013104473825700_bib84","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with heparin in critically ill patients with Covid-19","volume":"385","author":"REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators","year":"2021","journal-title":"N Engl J Med"},{"key":"2024013104473825700_bib85","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11239-022-02766-7","article-title":"Risk of venous thromboembolic events after COVID-19 infection: a systematic review and meta-analysis","volume":"55","author":"Zuin","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"2024013104473825700_bib86","doi-asserted-by":"crossref","first-page":"107602962211484","DOI":"10.1177\/10760296221148477","article-title":"Post-discharge thromboembolic events in COVID-19 patients: a review on the necessity for prophylaxis","volume":"29","author":"Mehrabi","year":"2023","journal-title":"Clin Appl Thromb Hemost"},{"key":"2024013104473825700_bib87","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(21)02392-8","article-title":"MICHELLE Investigators. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial","volume":"399","author":"Ramacciotti","year":"2022","journal-title":"Lancet North Am Ed"},{"key":"2024013104473825700_bib88","doi-asserted-by":"crossref","first-page":"10372","DOI":"10.3390\/ijms231810372","article-title":"Venous thromboembolic disease in COVID-19, pathophysiology, therapy and prophylaxis","volume":"23","author":"Dybowska","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024013104473825700_bib89","doi-asserted-by":"crossref","first-page":"102969","DOI":"10.1016\/j.ebiom.2020.102969","article-title":"Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients","volume":"59","author":"Buijsers","year":"2020","journal-title":"EBioMedicine"},{"key":"2024013104473825700_bib90","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"ACTION Coalition COVID-19 Brazil IV Investigators. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial","volume":"397","author":"Lopes","year":"2021","journal-title":"Lancet North Am Ed"},{"key":"2024013104473825700_bib91","doi-asserted-by":"crossref","first-page":"965790","DOI":"10.3389\/fmed.2022.965790","article-title":"Antiplatelet therapy for patients with COVID-19: systematic review and meta-analysis of observational studies and randomized controlled trials","volume":"9","author":"Zong","year":"2022","journal-title":"Front Med"},{"key":"2024013104473825700_bib92","first-page":"143","article-title":"Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","author":"RECOVERY Collaborative Group","year":"2022","journal-title":"Lancet North Am Ed"},{"key":"2024013104473825700_bib93","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/bloodadvances.2022007940","article-title":"American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients","volume":"6","author":"Cuker","year":"2022","journal-title":"Blood Adv"},{"key":"2024013104473825700_bib94","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1111\/jth.15808","article-title":"International Society on Thrombosis and Haemostasis. ISTH guidelines for antithrombotic treatment in COVID-19","volume":"20","author":"Schulman","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2024013104473825700_bib95","doi-asserted-by":"crossref","first-page":"175394472211050","DOI":"10.1177\/17539447221105013","article-title":"Predictors and mortality risk of venous thromboembolism in patients with COVID-19: systematic review and meta-analysis of observational studies","volume":"16","author":"Agarwal","year":"2022","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2024013104473825700_bib96","doi-asserted-by":"crossref","first-page":"e2022886","DOI":"10.1001\/jamanetworkopen.2020.22886","article-title":"GARFIELD-VTE Investigators. Assessment of outcomes among patients with venous thromboembolism with and without chronic kidney disease","volume":"3","author":"Goto","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2024013104473825700_bib97","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1515\/cclm-2022-0633","article-title":"D-dimer: old dogmas, new (COVID-19) tricks","volume":"61","author":"Lippi","year":"2023","journal-title":"Clin Chem Lab Med"},{"key":"2024013104473825700_bib98","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.amjmed.2013.12.003","article-title":"D-dimer to rule out pulmonary embolism in renal insufficiency","volume":"127","author":"Lindner","year":"2014","journal-title":"Am J Med"},{"key":"2024013104473825700_bib99","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.3324\/haematol.2018.213322","article-title":"The diagnostic performance of renal function-adjusted D-dimer testing in individuals suspected of having venous thromboembolism","volume":"104","author":"Cate","year":"2019","journal-title":"Haematologica"},{"key":"2024013104473825700_bib100","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1111\/jth.15809","article-title":"International Society on Thrombosis and Haemostasis. Good practice statements for antithrombotic therapy in the management of COVID-19: guidance from the SSC of the ISTH","volume":"20","author":"Spyropoulos","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2024013104473825700_bib101","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/jrms.JRMS_875_20","article-title":"Anticoagulation therapy in COVID-19 patients with chronic kidney disease","volume":"26","author":"Shafiee","year":"2021","journal-title":"J Res Med Sci"},{"key":"2024013104473825700_bib102","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1007\/s11239-020-02301-6","article-title":"Filter clotting with continuous renal replacement therapy in COVID-19","volume":"51","author":"Endres","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"2024013104473825700_bib103","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1186\/s13063-020-04814-0","article-title":"Cov-hep study: heparin in standard anticoagulation based on citrate for continuous veno-venous hemodialysis in patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial","volume":"21","author":"Lins","year":"2020","journal-title":"Trials"},{"key":"2024013104473825700_bib104","doi-asserted-by":"crossref","first-page":"104413","DOI":"10.1016\/j.ebiom.2022.104413","article-title":"Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes","volume":"87","author":"Reese","year":"2023","journal-title":"EBioMedicine"},{"key":"2024013104473825700_bib105","doi-asserted-by":"crossref","first-page":"e1003406","DOI":"10.1371\/journal.pmed.1003406","article-title":"Acute kidney injury associated with COVID-19: a retrospective cohort study","volume":"17","author":"Kolhe","year":"2020","journal-title":"PLoS Med"},{"key":"2024013104473825700_bib106","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/ndt\/gfab303","article-title":"Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study","volume":"37","author":"Sullivan","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2024013104473825700_bib107","doi-asserted-by":"crossref","first-page":"101724","DOI":"10.1016\/j.eclinm.2022.101724","article-title":"Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: an international multi-centre observational cohort study","volume":"55","author":"Tan","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2024013104473825700_bib108","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1681\/ASN.2021060734","article-title":"Kidney outcomes in long COVID","volume":"32","author":"Bowe","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2024013104473825700_bib109","doi-asserted-by":"crossref","first-page":"100552","DOI":"10.1016\/j.eclinm.2020.100552","article-title":"Incorporating kidney disease measures into cardiovascular risk prediction: development and validation in 9 million adults from 72 datasets","volume":"27","author":"Matsushita","year":"2020","journal-title":"eClinicalMedicine"},{"key":"2024013104473825700_bib110","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"key":"2024013104473825700_bib111","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41591-022-01689-3","article-title":"Long-term cardiovascular outcomes of COVID-19","volume":"28","author":"Xie","year":"2022","journal-title":"Nat Med"},{"key":"2024013104473825700_bib112","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1681\/ASN.2016010105","article-title":"AKI and long-term risk for cardiovascular events and mortality","volume":"28","author":"Odutayo","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2024013104473825700_bib113","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/pathophysiology30020020","article-title":"Risk factors and clinical characteristics of acute kidney injury in patients with COVID-19: a systematic review and meta-analysis","volume":"30","author":"Hidayat","year":"2023","journal-title":"Pathophysiology"},{"key":"2024013104473825700_bib114","doi-asserted-by":"crossref","first-page":"n693","DOI":"10.1136\/bmj.n693","article-title":"Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study","volume":"372","author":"Ayoubkhani","year":"2021","journal-title":"BMJ"},{"key":"2024013104473825700_bib115","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41591-022-01689-3","article-title":"Long-term cardiovascular outcomes of COVID-19","volume":"28","author":"Xie","year":"2022","journal-title":"Nat Med"},{"key":"2024013104473825700_bib116","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3390\/diagnostics13030491","article-title":"Long COVID syndrome and cardiovascular manifestations: a systematic review and meta-analysis","volume":"13","author":"Shrestha","year":"2023","journal-title":"Diagnostics"},{"key":"2024013104473825700_bib117","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/ckj\/sfab166","article-title":"Long-term impact of COVID-19 among maintenance haemodialysis patients","volume":"15","author":"Chawki","year":"2022","journal-title":"Clin Kidney J"},{"key":"2024013104473825700_bib118","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/ckj\/sfab248","article-title":"Increased 1-year mortality in haemodialysis patients with COVID-19: a prospective, observational study","volume":"15","author":"Carriazo","year":"2022","journal-title":"Clin Kidney J"},{"key":"2024013104473825700_bib119","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3390\/vaccines11020208","article-title":"Can COVID-19 vaccines induce premature non-communicable diseases: where are we heading to?","volume":"11","author":"Hromi\u0107-Jahjefendi\u0107","year":"2023","journal-title":"Vaccines"},{"key":"2024013104473825700_bib120","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jacc.2022.12.006","article-title":"N3C Consortium. Impact of vaccination on major adverse cardiovascular events in patients with COVID-19 infection","volume":"81","author":"Jiang","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024013104473825700_bib121","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.2022.12992","article-title":"Association between vaccination and acute myocardial infarction and ischemic stroke after COVID-19 infection","volume":"328","author":"Kim","year":"2022","journal-title":"JAMA"},{"key":"2024013104473825700_bib122","doi-asserted-by":"crossref","first-page":"101077","DOI":"10.1016\/j.cpcardiol.2021.101077","article-title":"Clinical cardiovascular adverse events reported post-covid-19 vaccination: are they a real risk?","volume":"47","author":"Hana","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"2024013104473825700_bib123","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1681\/ASN.2022010046","article-title":"The Impact of vaccination on incidence and outcomes of SARS-CoV-2 infection in patients with kidney failure in Scotland","volume":"33","author":"Bell","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2024013104473825700_bib124","article-title":"Lessons from","author":"Quiroga","year":"2022","journal-title":"Nefrologia (Engl Ed)"},{"key":"2024013104473825700_bib125","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/ckj\/sfac249","article-title":"RECOVAC Collaborators. Impact of immunosuppressive treatment and type of SARS-CoV-2 vaccine on antibody levels after three vaccinations in patients with chronic kidney disease or kidney replacement therapy","volume":"16","author":"Bouwmans","year":"2023","journal-title":"Clin Kidney J"},{"key":"2024013104473825700_bib126","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/ckj\/sfac169","article-title":"SENCOVAC collaborative network. Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study","volume":"15","author":"Quiroga","year":"2022","journal-title":"Clin Kidney J"},{"key":"2024013104473825700_bib127","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.kint.2022.01.022","article-title":"COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment","volume":"101","author":"El Karoui","year":"2022","journal-title":"Kidney Int"},{"key":"2024013104473825700_bib128","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet North Am Ed"},{"key":"2024013104473825700_bib129","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/ndt\/gfac307","article-title":"Humoral response after the fourth dose of the SARS-CoV-2 vaccine in the CKD spectrum: a prespecified analysis of the SENCOVAC study","volume":"38","author":"Quiroga","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2024013104473825700_bib130","doi-asserted-by":"crossref","first-page":"116","DOI":"10.12688\/wellcomeopenres.15933.1","article-title":"Baseline results of a living systematic review for COVID-19 clinical trial registrations","volume":"5","author":"Maguire","year":"2020","journal-title":"Wellcome Open Res"},{"key":"2024013104473825700_bib131","doi-asserted-by":"crossref","first-page":"60","DOI":"10.12688\/wellcomeopenres.15821.1","article-title":"A living systematic review protocol for COVID-19 clinical trial registrations","volume":"5","author":"Maguire","year":"2020","journal-title":"Wellcome Open Res"},{"key":"2024013104473825700_bib132","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial","volume":"324","author":"Angus","year":"2020","journal-title":"JAMA"},{"key":"2024013104473825700_bib133","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Group","year":"2021","journal-title":"N Engl J Med"},{"key":"2024013104473825700_bib134","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":". Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results","volume":"384","author":"Pan","year":"2021","journal-title":"N Engl J Med"},{"key":"2024013104473825700_bib135","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa2033130","article-title":"A neutralizing monoclonal antibody for hospitalized patients with Covid-19","volume":"384","author":"ACTIV-3\/TICO LY-CoV555 Study Group","year":"2021","journal-title":"N Engl J Med"},{"key":"2024013104473825700_bib136","first-page":"m3379","article-title":"A living WHO guideline on drugs for covid-19","volume":"370","author":"Lamontagne","year":"2020","journal-title":"BMJ"},{"key":"2024013104473825700_bib137","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"324","author":"Sterne","year":"2020","journal-title":"JAMA"},{"key":"2024013104473825700_bib138","doi-asserted-by":"crossref","first-page":"n2231","DOI":"10.1136\/bmj.n2231","article-title":"Antibody and cellular therapies for treatment of Covid-19: a living systematic review and network meta-analysis","volume":"374","author":"Siemieniuk","year":"2021","journal-title":"BMJ"},{"key":"2024013104473825700_bib139","article-title":"COVID-19 Interactions","author":"The Liverpool Drug Interactions Group","year":"2023"},{"key":"2024013104473825700_bib140","article-title":"The Renal Drug database","author":"UK Renal Pharmacy Group","year":"2023"},{"key":"2024013104473825700_bib141","article-title":"COVID-19 rapid guideline: managing COVID-19","author":"The National Institute for Health and Care Excellence","year":"2022"},{"key":"2024013104473825700_bib142","doi-asserted-by":"crossref","first-page":"e0279765","DOI":"10.1371\/journal.pone.0279765","article-title":"Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function","volume":"18","author":"Seethapathy","year":"2023","journal-title":"PLoS One"},{"key":"2024013104473825700_bib143","doi-asserted-by":"crossref","first-page":"100207","DOI":"10.1016\/j.clinpr.2022.100207","article-title":"Use of remdesivir for COVID-19 pneumonia in patients with advanced kidney disease: a retrospective multicenter study","volume":"16","author":"Stancampiano","year":"2022","journal-title":"Clin Infect Pract"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfad170\/52302840\/gfad170.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/2\/177\/56437456\/gfad170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/2\/177\/56437456\/gfad170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T05:13:30Z","timestamp":1706678010000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/39\/2\/177\/7285814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":143,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,9,28]]},"published-print":{"date-parts":[[2024,1,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfad170","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,9,28]]}}}